首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

2126425

數位生物標記市場－策略分析與預測（2026-2035）

Digital Biomarkers Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

數位生物標記市場預計將從 2026 年的 51.8 億美元成長到 2035 年的 196.3 億美元，複合年成長率為 16.0%。

數位生物標記市場正經歷重大變革，其驅動力源於持續健康監測、遠端病患管理和數據驅動醫療的模式轉移。這一市場演變的特點是，人們日益認知到，透過互聯技術收集的可量化生理和行為數據能夠提供客觀、真實的洞察，從而支持疾病評估、治療監測以及在傳統臨床環境之外的醫療決策。穿戴式裝置、智慧型手機平台、人工智慧和先進分析技術的融合，使得收集持續、擴充性且日益具有臨床意義的健康數據成為可能。醫療保健系統需要擴充性的方法來追蹤患者在傳統環境之外的健康狀況，而數位監測框架的整合正在不斷推進，以提高患者參與度和治療效果。隨著臨床試驗對客觀、持續的療效測量需求增加，製藥公司正在擴大數位生物標記的應用。監管機構也日益認知到數位化產生的健康證據的價值，這不僅有助於加強臨床決策，還提高了對數據品質和檢驗的期望。隨著市場對遠端監測平台、人工智慧驅動的分析和數位臨床試驗解決方案的大量投資，數位生物標記正在成為現代醫療保健和精準醫療的基本要素。

市場促進因素

遠端患者監護的擴展是數位生物標記市場的主要驅動力。遠端患者監護允許對患者健康狀況進行持續監測，即使患者不在醫療機構內。隨著醫療專業人員需要客觀的測量數據來支持早期療育和疾病管理，對數位生物標記的需求也在不斷成長。這項需求促使醫療系統採用能夠產生可靠的真實世界數據的技術。技術開發商正在擴展互聯監測平台，以提高其可及性和臨床整合性。因此，數位生物標記在慢性病管理計畫中的應用日益廣泛，從而推動了市場的持續成長。穿戴式健康技術的日益普及正在產生真實世界的健康訊息，進一步加速了市場成長。穿戴式裝置能夠產生大量的生理和行為健康數據。隨著消費者擴大使用互聯設備來監測自身健康狀況，對數位生物標記的需求也不斷成長。這一趨勢為醫療機構提供了將患者產生的數據整合到臨床工作流程中的機會。科技公司正致力於提升感測器的性能和分析能力，以提高數據品質。因此，源自穿戴式裝置的數位生物標記在醫療領域的應用正在不斷擴展。分散式臨床試驗的擴展正在推動遠端資料收集中數位生物標記的應用。臨床研究越來越依賴遠距和以患者為中心的試驗模式。分散式臨床試驗需要能夠在研究中心之外持續收集的客觀測量數據，因此對數位生物標記的需求不斷成長。這種轉變對依賴面對面諮商的傳統調查方法提出了挑戰。申辦方正在整合數位健康技術，以增強受試者的參與度並提高數據收集效率。人工智慧和數據分析的進步正在提升數位生物標記解決方案的臨床有效性和擴充性。數位生物標記依賴先進的分析能力，將原始數據轉化為具有臨床意義的見解。數位健康資料集的規模和複雜性不斷成長，推動了對先進分析方法的需求。

市場限制因素

數位生物標記需要強力的證據來證明其在不同患者群體中的可靠性和臨床有效性，而建立臨床有效性仍然是一項挑戰。這些嚴格的證據要求為開發人員帶來了巨大的時間和成本負擔。醫療保健相關人員要求對敏感的患者資訊進行嚴格保護，而對資料隱私和網路安全的擔憂限制了其應用。健康數據的高度敏感度也帶來了額外的管治要求。互通性限制仍然是一個主要挑戰，因為醫療保健系統通常使用分散的數位基礎設施和不相容的數據標準。缺乏標準化的資料格式也帶來了整合方面的挑戰。監管的不確定性和不斷變化的框架給旨在將數位生物標記解決方案商業化的開發人員帶來了合規性方面的挑戰。

對技術和生物標記類型的深入了解

技術趨勢的特點是整合式數位健康生態系統和人工智慧驅動的分析日益重要。穿戴式裝置持續監測生理功能和活動量。基於智慧型手機的平台只需極少的額外硬體即可實現廣泛可及的數據採集。聯網醫療設備支援針對特定疾病的臨床級監測。基於感測器的系統能夠測量特定的健康參數。軟體和分析平台將原始數據轉化為臨床適用的見解。細分市場分析表明，生理生物標記是主要關注點，因為持續監測生命徵象能夠提供客觀的健康狀況資訊。隨著醫療服務提供者越來越尋求對患者健康狀況的多方面觀點，需求正在轉向行為、認知、睡眠和運動生物標記。神經病學是一個關鍵的應用領域，因為持續監測能夠更好地評估涉及細微生理和行為變化的疾病以及治療效果。心血管、呼吸、精神、代謝和腫瘤學是重要且快速成長的應用領域。製藥和生物技術公司在主要終端用戶領域佔據主導地位，而醫療服務提供者和臨床研究機構也在擴大數位健康技術的應用。隨著數位健康資料集在規模、複雜性和臨床意義方面持續成長，人工智慧的整合變得日益重要。各機構正在提升計算能力，以改善疾病預測、治療監測和個人化醫療服務。

競爭格局與策略展望

競爭格局既包括成熟的科技公司，也包括專注於數位健康、分析和臨床研究的機構。蘋果公司憑藉其廣泛的消費性電子設備普及率和大規模的健康監測功能，保持著獨特的戰略地位，並不斷增強與健康相關的功能，支持心血管監測、運動表現評估、睡眠分析和健康追蹤。 Verily 的獨特之處在於，它將資料科學專長與醫療和生命科學創新相結合，擴展了其數位平台，以支援持續的健康數據收集和高級分析。 Biofourmis 的差異化優勢在於專注於人工智慧驅動的遠端監測和預測性健康分析，不斷擴展其預測分析能力，將持續的生理數據轉化為可操作的健康洞察。 ActiGraph 的策略重要性在於，隨著臨床研究越來越依賴能夠產生客觀數位終點的檢驗穿戴式技術，該公司正在擴展其穿戴式監測和分析工具，以確保數據品質並獲得監管部門的批准。 Koneksa Health 的差異化優勢在於專注於開發用於臨床研究和藥物應用的數位生物標記物，致力於開發旨在幫助產生符合監管標準的證據的數位生物標記解決方案。 Empatica憑藉其穿戴式技術在臨床和研究應用中支援穩健且連續的生理監測，並透過增強感測器技術和分析能力來提高監測精度，從而確立了其獨特的市場地位。 AliveCor專注於數位心血管監測和基於心電圖(ECG)的健康評估，保持了其競爭力並擴展了其數位心臟病學能力。 Medable憑藉其在分散式臨床試驗基礎設施和數位研究平台的領先地位脫穎而出，並擴展了其數位臨床試驗解決方案，該方案整合了穿戴式技術、病人參與工具和遠端結果測量。每家公司都在透過穿戴式感測器、人工智慧驅動的分析和數位臨床試驗平台的創新來擴展產品系列。在產生檢驗的數位生物標記和真實世界證據的需求推動下，科技公司、醫療保健提供者和製藥公司之間的策略合作夥伴關係正在增加。地理擴張仍然是關鍵的策略重點，各公司都將目光投向了快速成長的亞太地區和新興市場，這些地區的數位醫療基礎設施正在不斷擴展。

簡明結論

受遠端患者監護、穿戴式技術普及和人工智慧分析等因素的推動，數位生物標記市場預計將持續成長。從間歇性醫療保健向持續性健康智慧的轉變，標誌著醫療服務模式的根本性變革。儘管臨床檢驗、資料隱私和互通性方面仍存在挑戰，但對技術、夥伴關係和證據產生的策略性投資正為市場領導提供持續的競爭優勢。長期市場前景依然樂觀，數位生物標記正從單純的輔助性健康監測工具發展成為現代醫療服務的重要組成部分，在全球醫療保健系統中支持疾病預防管理、個人化治療和改善患者預後。

本報告的主要益處：

深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
實用建議：我們支援制定策略決策，以開發新的收入來源。
適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
競爭對手定位、策略和市場佔有率分析
營收成長率及預測分析：依業務板塊及地區（國家）分類
企業概況（策略、產品、財務資訊、關鍵趨勢等）

市場定義和範圍
行業概覽
產業變化
主要市場趨勢
實際成果值市場規模分析
市場預測分析
數位生物標記的生態系統分析
用戶採納狀況分析
對聯網醫療基礎設施的評估
遠端監控現狀分析
對患者產生的健康數據進行分析
臨床效用與檢驗框架
數位生物標記在精準醫療中的作用

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態
相關人員生態系統分析
數位健康整合的現狀

第6章：創新趨勢

數位生物標記的新興技術
產品創新趨勢
臨床實驗分析
數位生物標記開發平臺分析
穿戴式感測器創新趨勢
人工智慧與機器學習的融合
利用智慧型手機開發生物標記
真實世界數據使用趨勢
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求
數位健康監管指南的分析
資料隱私和安全要求

第8章：數位生物標記市場：展望分析

分析：按技術平台
分析：依生物標記類型
分析：透過臨床應用
分析：透過資料收集方法
分析：按最終使用者環境
分析：按檢驗狀態
分析：按治療領域
分析：依部署方式

第9章：數位生物標記市場：細分市場分析

依生物標誌類型
- 生理生物標記
- 行為生物標記
- 認知生物標記
- 睡眠生物標記
- 移動性和活動性生物標記
透過技術平台
- 穿戴式裝置
- 基於智慧型手機的平台
- 連網醫療設備
- 基於感測器的系統
- 軟體和分析平台
臨床應用
- 神經病學
- 心血管疾病
- 呼吸系統疾病
- 精神健康障礙
- 代謝性疾病
- 瘤
最終用戶
- 製藥和生物技術公司
- 醫療保健提供者
- 臨床研究機構
- 學術和研究機構
- 病患與消費者健康用戶
資料收集方法
- 被動監測
- 主動監測
- 混合監測

第10章：數位生物標記市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：數位生物標記市場：國別分析

美國
加拿大
德國
英國
法國
荷蘭
日本
中國
韓國
澳洲
印度
新加坡

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布
競爭基準
數位健康領域的夥伴關係分析

第13章：公司簡介

Apple Inc.
Verily Life Sciences LLC
Biofourmis Pte. Ltd.
ActiGraph, LLC
Koneksa Health, Inc.
Empatica Inc.
AliveCor, Inc.
Medable Inc.
Huma Therapeutics Ltd.
Biogen Inc.
Roche Holding AG
Evidation Health, Inc.
Philips Healthcare
Garmin Ltd.
Oura Health Oy

第14章：數位生物標記市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資
數位醫療領域的投資趨勢
遠端監測領域的資金籌措趨勢
人工智慧醫療保健和分析領域的投資分析

第16章：未來展望

主要成長機遇
未來產業趨勢
利用人工智慧發展生物標記
擴大持續健康監測範圍
整合真實世界證據的未來
長期市場展望（2035 年）

簡介目錄

Product Code: KSI061615676

The Digital Biomarkers Market is anticipated to grow at a CAGR of 16.0% from USD 5.18 billion in 2026 to USD 19.63 billion in 2035.

The digital biomarkers market is undergoing significant transformation driven by the paradigm shift toward continuous health monitoring, remote patient management, and data-driven healthcare. The market's evolution is characterized by the growing recognition that quantifiable physiological and behavioral data collected through connected technologies can provide objective, real-world insights that support disease assessment, treatment monitoring, and healthcare decision-making outside traditional clinical environments. The convergence of wearable devices, smartphone-based platforms, artificial intelligence, and advanced analytics is enabling continuous, scalable, and increasingly clinically relevant health data collection. Healthcare systems are seeking scalable methods for tracking patient health beyond conventional care settings, driving integration of digital monitoring frameworks to improve patient engagement and treatment effectiveness. Pharmaceutical companies are increasing use of digital biomarkers because clinical trials require more objective and continuous outcome measurements. Regulatory authorities increasingly recognize the value of digitally generated health evidence, strengthening clinical decision-making and raising expectations regarding data quality and validation. The market is witnessing significant investment in remote monitoring platforms, AI-enabled analytics, and digital clinical trial solutions, positioning digital biomarkers as a foundational component of modern healthcare delivery and precision medicine.

Market Drivers

The expansion of remote patient monitoring represents the primary driver for the digital biomarkers market. Remote patient monitoring enables continuous observation of patient health outside healthcare facilities. Demand for digital biomarkers is increasing because healthcare providers require objective measures that support early intervention and disease management. This requirement creates pressure on healthcare systems to adopt technologies capable of generating reliable real-world data. Technology developers are expanding connected monitoring platforms to improve accessibility and clinical integration. The outcome is growing utilization of digital biomarkers across chronic disease management programs, resulting in sustained growth in digital biomarker utilization. The increasing adoption of wearable health technologies is further accelerating market growth through generation of real-world health information. Wearable devices generate large volumes of physiological and behavioral health information. Demand for digital biomarkers is rising because consumers increasingly use connected devices to monitor health and wellness. This trend creates opportunities for healthcare organizations to incorporate patient-generated data into clinical workflows. Technology companies are enhancing sensor capabilities and analytical performance to improve data quality. The result is broader use of wearable-derived digital biomarkers in healthcare applications. The growth of decentralized clinical trials is driving adoption of digital biomarkers for remote data collection. Clinical research increasingly relies on remote and patient-centric study models. Demand for digital biomarkers is increasing because decentralized trials require objective measures that can be collected continuously outside research sites. This transition creates challenges for traditional assessment methodologies that depend on in-person visits. Sponsors are integrating digital health technologies to improve participant engagement and data collection efficiency. Advancements in artificial intelligence and data analytics are improving the clinical relevance and scalability of digital biomarker solutions. Digital biomarkers depend on advanced analytical capabilities to convert raw data into clinically meaningful insights. Demand for sophisticated analytics is rising because digital health datasets continue expanding in volume and complexity.

Market Restraints

Clinical validation challenges persist because digital biomarkers require robust evidence demonstrating reliability and clinical relevance across diverse patient populations. The rigorous evidence requirements create significant time and cost burdens for developers. Data privacy and cybersecurity concerns limit adoption because healthcare stakeholders require strong protection of sensitive patient information. The sensitive nature of health data creates additional governance requirements. Interoperability limitations remain significant because healthcare systems often utilize fragmented digital infrastructures and incompatible data standards. The lack of standardized data formats creates challenges for integration. Regulatory uncertainty and evolving frameworks create compliance challenges for developers seeking to commercialize digital biomarker solutions.

Technology and Biomarker Type Insights

The technology landscape is characterized by the growing importance of integrated digital health ecosystems and AI-enabled analytics. Wearable devices provide continuous physiological and activity monitoring. Smartphone-based platforms offer widely accessible data collection with minimal additional hardware. Connected medical devices support clinical-grade monitoring for specific conditions. Sensor-based systems enable specialized health parameter measurement. Software and analytics platforms transform raw data into clinically actionable insights. The segment analysis reveals that physiological biomarkers represent a major focus because continuous monitoring of vital signs provides objective health status information. Demand is shifting toward behavioral, cognitive, sleep, and mobility biomarkers because healthcare providers increasingly seek multidimensional views of patient health. Neurology represents a key application area because continuous monitoring can improve disease assessment and treatment evaluation for conditions involving subtle physiological and behavioral changes. Cardiovascular diseases, respiratory diseases, mental health disorders, metabolic disorders, and oncology represent significant and growing application areas. Pharmaceutical and biotechnology companies represent the leading end-user segment, with healthcare providers and clinical research organizations expanding digital health utilization. The integration of AI is becoming increasingly important because digital health datasets continue expanding in volume, complexity, and clinical significance. Organizations are strengthening computational capabilities to improve disease prediction, treatment monitoring, and personalized care delivery.

Competitive and Strategic Outlook

The competitive landscape features established technology companies alongside specialized digital health, analytics, and clinical research organizations. Apple maintains a strategically distinct position because it combines large-scale consumer device adoption with advanced health monitoring capabilities, enhancing health-focused capabilities that support cardiovascular monitoring, mobility assessment, sleep analysis, and wellness tracking. Verily occupies a distinctive position because it combines data science expertise with healthcare and life sciences innovation, expanding digital platforms that support continuous health data collection and advanced analytical capabilities. Biofourmis differentiates itself through its focus on AI-driven remote monitoring and predictive health analytics, expanding predictive analytics capabilities that transform continuous physiological data into actionable health insights. ActiGraph maintains strategic relevance because clinical research increasingly depends on validated wearable technologies capable of generating objective digital endpoints, expanding wearable monitoring capabilities and analytical tools to improve data quality and regulatory acceptance. Koneksa Health differentiates itself through its focus on digital biomarker development for clinical research and pharmaceutical applications, advancing digital biomarker solutions designed to support regulatory-grade evidence generation. Empatica occupies a unique position because its wearable technologies support continuous physiological monitoring with strong clinical and research applications, enhancing sensor technologies and analytical capabilities to improve monitoring accuracy. AliveCor maintains competitive strength through its focus on digital cardiovascular monitoring and ECG-based health assessment, expanding digital cardiology capabilities. Medable differentiates itself through its leadership in decentralized clinical trial infrastructure and digital research platforms, expanding digital trial solutions that integrate wearable technologies, patient engagement tools, and remote outcome measurements. Companies are pursuing product portfolio expansion through innovation in wearable sensors, AI-enabled analytics, and digital clinical trial platforms. Strategic collaborations between technology companies, healthcare providers, and pharmaceutical companies are increasing, driven by the need for validated digital biomarkers and real-world evidence generation. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where digital health infrastructure is expanding.

Short Conclusion

The digital biomarkers market is positioned for sustained growth driven by the convergence of remote patient monitoring, wearable technology adoption, and AI-enabled analytics. The transition from episodic healthcare toward continuous health intelligence represents a fundamental shift in healthcare delivery. While challenges related to clinical validation, data privacy, and interoperability persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with digital biomarkers evolving from supplemental health monitoring tools into foundational components of modern healthcare delivery, supporting proactive disease management, personalized treatment, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Digital Biomarkers Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Digital Biomarker Ecosystem Analysis
3.8 User Adoption Analysis
3.9 Connected Healthcare Infrastructure Assessment
3.10 Remote Monitoring Landscape Analysis
3.11 Patient-Generated Health Data Analysis
3.12 Clinical Utility and Validation Framework
3.13 Role of Digital Biomarkers in Precision Medicine

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape
5.4 Stakeholder Ecosystem Analysis
5.5 Digital Health Integration Landscape

6. Innovation Landscape

6.1 Emerging Technologies in Digital Biomarkers
6.2 Product Innovation Trends
6.3 Clinical Trial Analysis
6.4 Digital Biomarker Development Pipeline Analysis
6.5 Wearable Sensor Innovation Trends
6.6 AI and Machine Learning Integration
6.7 Smartphone-Based Biomarker Development
6.8 Real-World Data Utilization Trends
6.9 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements
7.4 Digital Health Regulatory Guidance Analysis
7.5 Data Privacy and Security Requirements

8. Digital Biomarkers Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker Type
8.3 Analysis by Clinical Application
8.4 Analysis by Data Collection Method
8.5 Analysis by End-user Environment
8.6 Analysis by Validation Status
8.7 Analysis by Therapeutic Area
8.8 Analysis by Deployment Model

9. Digital Biomarkers Market Segment Analysis (2021-2035)

9.1 By Biomarker Type
- 9.1.1 Physiological Biomarkers
- 9.1.2 Behavioral Biomarkers
- 9.1.3 Cognitive Biomarkers
- 9.1.4 Sleep Biomarkers
- 9.1.5 Mobility and Activity Biomarkers
9.2 By Technology Platform
- 9.2.1 Wearable Devices
- 9.2.2 Smartphone-Based Platforms
- 9.2.3 Connected Medical Devices
- 9.2.4 Sensor-Based Systems
- 9.2.5 Software and Analytics Platforms
9.3 By Clinical Application
- 9.3.1 Neurology
- 9.3.2 Cardiovascular Diseases
- 9.3.3 Respiratory Diseases
- 9.3.4 Mental Health Disorders
- 9.3.5 Metabolic Disorders
- 9.3.6 Oncology
9.4 By End User
- 9.4.1 Pharmaceutical and Biotechnology Companies
- 9.4.2 Healthcare Providers
- 9.4.3 Clinical Research Organizations
- 9.4.4 Academic and Research Institutions
- 9.4.5 Patients and Consumer Health Users
9.5 By Data Collection Method
- 9.5.1 Passive Monitoring
- 9.5.2 Active Monitoring
- 9.5.3 Hybrid Monitoring